Dawn R. Mattoon
Directeur Général chez Mercy Bioanalytics, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Masoud Toloue | M | 43 | 3 ans | |
Paul W. Blavin | M | - |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 6 ans |
Joseph Sedlak | M | - |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 6 ans |
Sarah Hlavinka McConnell | F | 59 | 5 ans | |
Laurie Olson | F | 61 | 3 ans | |
Karen Flynn | F | 61 | 2 ans | |
Daniel Pikora | M | 49 | 2 ans | |
Sonja Perkins | F | 57 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Paul Meister | M | 71 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Stanley Lapidus | M | 75 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | - |
Myla Lai-Goldman | M | 66 |
Mercy Bioanalytics, Inc.
Mercy Bioanalytics, Inc. Pharmaceuticals: MajorHealth Technology The American company was founded in 2018 by Joseph Sedlak and Paul W. Blavin, and Dawn R. Mattoon has been the CEO of the company since 2022. Mercy Bioanalytics utilizes the patented Mercy Halo liquid biopsy platform to detect stage I cancer, which is most treatable, by analyzing single extracellular vesicles (EVs) that carry unique cancer signatures from their parent cells. The company's initial focus is on the early detection of ovarian and lung cancers, which are difficult to detect and often go undetected until it is too late to cure. The Mercy Halo test makes early-stage cancer detection 100,000 times easier by analyzing EVs found in blood that are specific to their parent cells. | 1 ans |
Erica Bell | F | 51 | 2 ans | |
Alexandra Phillips | F | - | 2 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Shawn Stetson | M | 47 | 3 ans | |
Ernest Orticerio | M | 60 | 7 ans | |
John Connolly | M | 71 | 8 ans | |
Gerrit Smith | M | - | 1 ans | |
Douglas Cole | M | 63 | 12 ans | |
Marijn Dekkers | M | 65 | 4 ans | |
John Fry | M | 62 | 3 ans | |
Michael Doyle | M | 68 | 3 ans | |
Richard Andy Keys | M | - | 2 ans | |
Denise Chittick | F | - | 1 ans | |
Richard Haigh | M | - | 1 ans | |
Paulo Carvalho | M | - | - | |
Amol Chaubal | M | 48 | 2 ans | |
William Geist | M | 55 | 1 ans | |
Amee Desjourdy | F | - | 1 ans | |
David H. Wilson | M | - | 9 ans | |
Jackson Streeter | M | - | 1 ans | |
James Foster | M | 73 |
Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. Medical SpecialtiesHealth Technology Cell Signaling Technology, Inc. manufactures and distributes research tools for cell function and diseases. It offers primary antibodies, activators and inhibitors, buffers and dyes, cellsimple, and cytokines. The company was founded in 1999 and is headquartered in Danvers, MA. | 4 ans |
Joseph S. Driscoll | M | 59 | 2 ans | |
Samira Amini | F | - | 2 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 33 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Dawn R. Mattoon
- Réseau Personnel